Spotlight
A selection of resources from across the Federation
Resource
IMAP Statement on Sex Worker-Centred Sexual and Reproductive Health Services
Our IMAP statement on delivering comprehensive, evidence‑based sexual and reproductive health services tailored to the needs of sex workers.
Most Popular This Week
Resource
|
IMAP Statement on Sex Worker-Centred Sexual and Reproductive Health Services
This statement is intended to provide guidance to Member Associations and Collaborative Partners across the Federation on delivering comprehensive, evidence‑based sexual and reproductive health (SR
Resource
|
IPPF in 2024: Financial Statements
We are a worldwide federation of national SRHR organizations working with and for communities and individuals. Our 119 Member Associations and 39 Collaborative Partners span 153 countries.
Resource
|
IMAP Statement on Advances in Emergency Contraception
The purpose of this statement is to review newly published data on increasing the effectiveness of levonorgestrel emergency contraceptive pills by using pre‑coital administration or combined with a
Resource
|
Technical Brief: Designing and Delivering Inclusive, Rights-Based Sexual and Reproductive Healthcare to Transgender and Gender Diverse People
IPPF’s commitment to person-centred care is at the heart of its strategy, Come Together (2023–2028).
Resource
|
Sexual and gender-based violence services and programming overview brief
The International Planned Parenthood Federation (IPPF) is pleased to be share this Sexual and Gender-based Violence Services and Programming overview document.
Resource
|
IPPF Storage Room poster
IPPF is pleased to be providing an important poster aimed at promoting safe and effective storage practices for medical supplies in your storage rooms.
Filter our resources by:
Resource
| 12 May 2025
IMAP Statement on Advances in Emergency Contraception
The purpose of this statement is to review newly published data on increasing the effectiveness of levonorgestrel emergency contraceptive pills by using pre‑coital administration or combined with a non‑steroidal anti‑inflammatory drug; the potential use of LNG‑ECP as a regular contraceptive method for infrequent sex; ulipristal acetate which is an established EC method and is now being studied combined with misoprostol for termination of early pregnancy; and the underutilization of low dose mifepristone as an EC method.
Resource
| 12 May 2025
IMAP Statement on Advances in Emergency Contraception
The purpose of this statement is to review newly published data on increasing the effectiveness of levonorgestrel emergency contraceptive pills by using pre‑coital administration or combined with a non‑steroidal anti‑inflammatory drug; the potential use of LNG‑ECP as a regular contraceptive method for infrequent sex; ulipristal acetate which is an established EC method and is now being studied combined with misoprostol for termination of early pregnancy; and the underutilization of low dose mifepristone as an EC method.
Resource
| 12 May 2025
IMAP Statement on Advances in Emergency Contraception
The purpose of this statement is to review newly published data on increasing the effectiveness of levonorgestrel emergency contraceptive pills by using pre‑coital administration or combined with a non‑steroidal anti‑inflammatory drug; the potential use of LNG‑ECP as a regular contraceptive method for infrequent sex; ulipristal acetate which is an established EC method and is now being studied combined with misoprostol for termination of early pregnancy; and the underutilization of low dose mifepristone as an EC method.
Resource
| 12 May 2025
IMAP Statement on Advances in Emergency Contraception
The purpose of this statement is to review newly published data on increasing the effectiveness of levonorgestrel emergency contraceptive pills by using pre‑coital administration or combined with a non‑steroidal anti‑inflammatory drug; the potential use of LNG‑ECP as a regular contraceptive method for infrequent sex; ulipristal acetate which is an established EC method and is now being studied combined with misoprostol for termination of early pregnancy; and the underutilization of low dose mifepristone as an EC method.
